AFMD News and Press, Affimed N.V. From 11/17/22

Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. The clinical-stage biotech's stock closed at $2.45 on Wednesday before opening at $2.37 on Thursday. It fell to $2.0801, the stock's 52-week low, in t...

Affimed N.V. (AFMD) Q3 2022 Earnings Conference Call November 15, 2022, 08:30 AM ET Company Participants Alex Fudukidis - Director of IR Adi Hoess - CEO Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fische...

Affimed press release ( NASDAQ: AFMD ): Q3 GAAP EPS of -€0.11. Revenue of €14.9M (+71.3% Y/Y). As of September 30, 2022, cash and cash equivalents totaled €222.9M compared to €197.6M on December 31, 2021. Based on the Company’s c...

AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a collaboration with Artiva Biotherapeutics; an Investigational New Drug (IND) application f...

German biotech Affimed N.V. ( NASDAQ: AFMD ) added ~7% on Thursday morning after data updates were made available from two Phase 1/2a clinical trials designed to test the company’s bispecific antibody in patients with solid tumors. The readouts from trials testing...

German biotech Affimed N.V. ( NASDAQ: AFMD ) jumped ~22% on Monday after announcing updated data for bispecific antibody AFM24 from two Phase 1/2a clinical trials in patients with solid tumors. The company said that results published ahead of the 37th Annual Meeting of t...

Hot Penny Stocks To Watch For CPI Week This could be one of the most volatile weeks for the stock market in 2022, and penny stocks could be at the top of mind for traders. Why focus on cheap stocks? Assuming you know how to manage risk, volatility is where money is made. When times ...

Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumor Initial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary...

HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release...

Germany's Affimed ( NASDAQ: AFMD ) stock rose ~22% on Thursday after the company said it signed an agreement with San Diego-based Artiva Biotherapeutics to jointly develop and commercialize a combination therapy to treat cancer. The combo therapy consists of Aff...